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Abstract
Ursodeoxycholate is used to treat primary biliary cirrhosis and is incorporated into hepatocyte plasma membranes. Its
steroid nucleus binds to the apolar domain of the membrane, in a similar position to cholesterol. Therefore the question
arises whether ursodeoxycholate has a similar effect on membrane structure and stability as cholesterol. Using differential
scanning calorimetry the thermotropic behavior of egg phosphatidylcholine and dimyristoylphosphatidylcholine were
studied after incubation with cholesterol or ursodeoxycholate. Large unilamellar vesicles were prepared with cholesterol
contents of 0–50%. Following incubation of these vesicles with different amounts of ursodeoxycholate, vesicle stability in a
gravitational field was investigated by measuring the phospholipid and cholesterol release. Vesicle size was studied by laser
light scattering after incubation with cheno- and ursodeoxycholate, and the release of entrapped carboxyfluorescein was
measured by means of fluorescence spectroscopy. Increasing cholesterol diminished the enthalpy of the phase transition in
the membrane. Ursodeoxycholate decreased the enthalpy of the phase transition at even lower concentrations. Lipid release
from vesicles in a high gravitational field diminished with increasing cholesterol content of the vesicles. Ursodeoxycholate
had a comparable effect, which increased as the cholesterol content of the vesicles was decreased. Chenodeoxycholate
damaged vesicles, whereas ursodeoxycholate did not. Cholesterol and ursodeoxycholate below its critical micellar
.concentration decreased the carboxyfluorescein release from vesicles induced by chenodeoxycholate. Thus like cholesterol,
ursodeoxycholate is incorporated into phospholipid model membranes and reduces the change in enthalpy of the gel to
liquid-crystalline phase transition. Like cholesterol ursodeoxycholate also maintains membrane stability and prevents
membrane damage induced by mechanical and chemical stress. q 1997 Elsevier Science B.V.
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1. Introduction
Bile salts are potent detergents which damage cell
membranes time- and dose-dependently. The effi-
ciency with which membrane lipids, such as choles-
terol and phospholipids, are solubilized in vitro gen-
erally increases with increasing bile salt hydrophobic-
w xity 1–3 . Damage to hepatocyte plasma membranes
by hydrophobic bile salts has been demonstrated in
w xanimal experiments 4,5 . Moreover, structural and
functional injury of hepatocyte membranes caused by
hydrophobic bile salts may play a role in the patho-
w xgenesis of cholestatic liver diseases in man 6 . Bile
salts may bind to basolateral hepatocyte membranes,
to cell organelle membranes, and especially to the
outside layer of the canalicular membrane following
their excretion. UDC protects against damage caused
w xby hydrophobic bile salts 7,8 , which seems in part
to depend on the amount of its membrane-bound
w xfraction 9 .
Recently it has been shown by EPR that UDC is
incorporated into the apolar domain of hepatocyte
w xplasma membranes in a similar way to cholesterol 9 .
The incorporation of cholesterol molecules into
phospholipid bilayers has a profound effect on the gel
w xto liquid-crystalline state of the membrane 10 and
this effect has been widely studied due to its rele-
w xvance to the function of biological membranes 11 .
Therefore the first aim of the present study was to
investigate whether UDC influences the gel to
liquid-crystalline state of phospholipid membranes in
a similar way to cholesterol. When a compound is
inserted into phospholipid membranes, it influences
or disturbs the cooperativity of the phospholipid
molecules and this is reflected in a modification of
w xthe endotherms or exotherms 12,13 during phase
transitions, e.g., transitions from the liquid crystal to
the gel state. DSC is widely employed as a method
for detecting phase transitions. The area under the
transition peak reflects the energy released or ab-
sorbed, and the width of the curve indicates the
number of molecules that undergo transition simulta-
neously.
The second aim of the study was to investigate the
stabilizing properties of UDC, cholesterol and phos-
pholipids on phospholipid-rich LUV. This was stud-
ied by measuring the release of CF entrapped in the
vesicles and by determining the vesicle size by laser
light scattering following incubation with CDC and
UDC. In addition the lipid release from the mem-
branes was measured following centrifugal forces. If
UDC stabilizes membranes to a similar extent as
cholesterol, this could be one of the modes of action
by which UDC protects basolateral hepatocyte mem-
branes in animal experiments and in vitro.
2. Material and methods
Bile salts were obtained from Calbiochem San
.Diego, CA ; their purity was )99% as determined
by thin-layer chromatography. EYL phosphati-
.dylcholine purity )99% , dimyristoylphosphatidyl-
 .choline purity )99% determined by thin-layer
 .chromatography, cholesterol purity )99% , CF and
buffer substances were from Sigma Deisenhofen,
.Germany .
( )2.1. Differential scanning calorimetry DSC
 . DSC measures the heat energy absorbed or re-
.leased by a sample as it undergoes an endothermic
 .or exothermic phase transition. DSC was performed
by means of a Mettler TA 3000rDSC 30 instrument
equipped with a liquid nitrogen cooling device Met-
.tler Instrumente AG, Greifensee, Switzerland . Base-
line fluctuations were below "1 mW at a heating
rate of 10 K miny1 with no peaks or shifts greater
than 0.1 mW. Scans were run at rates of dTrdts3 K
miny1. Enthalpy changes were determined by means
of a microcomputer which was integrated into the TA
3000rDSC 30 system. Scans were recorded with a
 .printer type PSM MK II Print swiss matrix . The
 .transition temperature T is given in 8C. For furtherc
characterisation of the transitions the change in en-
 w x.thalpy DH KJrmol and the broadening of the
 w xtransition peak expressed as DD the width mm at
w x.half maximum heightrmax height mm were plot-
ted against the molar concentration of the respective
 .addition cholesterol, UDC .
Samples were prepared from stock solutions of
100 mg EYLrml chloroform, 40 mg cholesterolrml
chloroform, 2 mg UDCrml methanol. Appropriate
amounts were collected to give molar ratios of
cholesterolrEYL: 0r100, 10r90, 20r80 corre-
.sponding to 0, 10, 20% cholesterol , and UDCrEYL:
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0r100, 5r95, 10r90, 15r85, 20r80 corresponding
.to 0, 5, 10, 15, 20% UDC , two series of experiments
were performed. Thereafter the solutions were dried
 .down in DSC pans aluminium, Vs40 ml under a
stream of nitrogen. After evaporation under vacuum
for at least 20 h, lipid mass was gravimetrically
determined using an electronic microbalance Mettler
.M3 . Absolute mass was determined to be 3–4 mg.
 20 ml buffer 10 mM sodium phosphate buffer pH
. .7.4 , 0.9% NaCl, 50% glycerin was added and the
pans were sealed. For complete hydration and equili-
bration the pans were kept at 408C for 24 h. Refer-
ence pans, containing 20 ml of the above buffer,
were handled in the same manner. 50% glycerin was
added to the buffer as antifreeze. In order to eliminate
influences of the antifreeze reagent on the phase
transition the concentration was kept constant. Heat-
ing curves were driven from y408C to q408C,
cooling curves from q408C to y408C.
In addition the effect of UDC on the phase transi-
tion of dimyristoylphosphatidylcholine was investi-
gated. The lipid was mixed with the bile salt to give
molar ratios of UDCrdimyristoylphosphatidyl-
choline: 0r100; 0.1r99.9; 0.5r99.5; 1r99; 3r97;
5r95. The procedure described above for DSC mea-
surements was performed, but without adding of
antifreeze. Heating curves were driven from 28C to
458C and cooling curves from 458 to 28C.
2.2. Bile salt solutions
The sodium salts of bile acids were dissolved in
 .sodium phosphate buffer 1 mM, pH 7.4 . UDC and
CDC were prepared in concentrations of 0.05–10
mM; if necessary the pH was adjusted to 7.4.
2.3. Vesicle preparation
EYL and cholesterol were dissolved in chloroform,
the lipid concentration was 20 mgrml solvent. Molar
ratios with a cholesterol content of 0–50% were
w xprepared 14 . 1 ml of the lipid solution was freeze-
dried and the lipid film was dissolved in 0.1 mM
 .sodium phosphate buffer pH 7.4, 258C . After
freeze-thawing 10 times the suspension was passed
20 times through a polycarbonate filter of a defined
 .  tmpore size 100 nm using an extruder LiposoFast ,
.Avestin Inc., Ottawa, Canada . Vesicle size was de-
 R,termined by laser light scattering Coulter Nanosizer
.details see below . Vesicles were freshly prepared for
each experiment.
2.4. Determination of ˝esicle stability
Vesicle stability against centrifugal forces was de-
termined using ultracentrifugation. 100 ml of vesicles
containing different amounts of cholesterol were in-
cubated with 3 ml of different bile salt solutions
UDC and CDC, 0.1–10 mM in sodium phosphate
.buffer, pH 7.4 at 258C. The suspension was shaken
gently every 10 min. After 30 min the sample was
centrifuged at 100 000=g for 30 min. Phospholipid
and cholesterol concentrations were determined pho-
 .tometrically Boehringer-Mannheim Test-Kit in the
suspension and in the supernatant. The lipid release
 .concentration in the supernatant was calculated as
the percentage of the total lipid concentration. LUV
in buffer served as the control.
2.5. Influence of bile salts on ˝esicle size
10 ml of vesicle suspension were incubated with
250 ml UDC or CDC 0.1–10 mM in sodium phos-
.phate buffer, pH 7.4, 258C for 10 min. The size of
the vesicles was determined by laser light scattering
 R.Coulter Nanosizer . The lower detection limit was
20 nm and the upper limit was 1000 nm, detection
time was 1 min.
2.6. Determination of carboxyfluorescein-efflux
 .EYL 20 mgrml were dispersed in sodium phos-
 .phate buffer 10 mM, pH 7.4 ; 6-CF was added to a
final concentration of 100 mM in the buffer. Since
this lipid-CF solution would not pass through the
polycarbonate filter due to the high viscosity, the
liposomes were prepared by probe sonication Bran-
.son Sonifier . Suspensions were sonified 6 times on
ice for 5 min under a continuous stream of nitrogen.
The CF in the extravesicular space was removed by
 .gel chromatography Sephadex-G 50 . After centrifu-
gation of the vesicle loaded columns at 10 000=g
w xfor 10 min, the eluate was collected 15 . The proce-
dure was repeated 4 times, until the CF was removed.
 .2 ml bile salt solution CDC or UDC were mixed
with 5 ml of the vesicle solution. The size of the
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sonicated vesicles were checked by laser light scatter-
ing and found to be 90"20 nm.
The fluorescence intensity I was monitored at 516
 .nm excitation at 492 nm on a Hitachi 650-10S
fluorescence spectrometer. The self quenching effect
of CF could be excluded, since the concentrations
used for detection were far below the quenching
w xconcentrations 15 . The intensity of the total amount
 .of CF I s100% value was determined after com-
plete destruction of the liposomes with 100 ml of a
 .Triton X-100 solution 10% vrv . The percentage of
w xCF released was calculated as follows 15 : %CF
 .  ..releaseds It-Io r I -Io =100, where t and o re-
fer to the time of sampling and to the instant when
bile salt solution was added to the liposomal suspen-
sion. The values of CF efflux after 60, 120 and 240
sec were calculated as % of the total CF fluorescence
intensity.
2.7. Reproducibility of data
All data shown are mean"standard error of at
least 3 individual measurements.
3. Results
3.1. DSC measurements
As has previously been described, increasing the
cholesterol content diminished the enthalpy of the
w xphase transition of the membrane 10 . The enthalpy
 .DH of the transition of EYL without cholesterol
 .was about 13 kJrmol lipid Table 1 . The transition
 .temperature T shifted only marginally from y9.28Cc
for EYL without cholesterol, to y10.98C with 20%
 .cholesterol Table 1 . The width of the transition
peak became broader with increasing amounts of
cholesterol. 20% cholesterol resulted in a maximum
broadening of the peak DDs1.59 heating scans,
.DDs1.68 cooling scans with a 53% reduction of
enthalpy in heating scans and 55% reduction in cool-
ing scans. The data obtained from the heating and the
cooling scans were similar, although the transition
temperature was lower for the cooling curve.
Addition of UDC to EYL resulted in a very similar
behavior of the phase transitions. The enthalpy of the
transition was decreased by the addition of UDC,
Table 1
Physicochemical data of heating scans on the thermotropic phase
 .transition of EYL and dimyristoylphosphatidylcholine DMPC
with increasing amounts of cholesterol or UDC
aw x w x w xAdditions mol% D H kJrmol T 8C DDc
EYL
100% 13.0"0.2 y9.2"0.7 0,8"0.05
Cholesterol
10% 10.1"0.02 y9.6"0.05 1.25"0.07
20% 6.1"0.03 y10.9"0.03 1.59"0.11
UDC
5% 9.31"0.04 y8.1"0.02 1.10"0.07
10% 8.15"0.02 y8.9"0.04 1.15"0.09
15% 7.08"0.05 y9.8"0.03 1.20"0.10
20% 6.46"0.07 y9.4"0.05 1.48"0.13
DMPC
100% 23.41"0.13 23.3"0.04 0.07"0.01
Cholesterol
10% 9.93"0.07 21.7"0.03 0.77"0.02
UDC
0.1% 22.30"0.15 23.5"0.07 0.07"0.01
0.5% 22.24"0.18 23.5"0.08 0.08"0.02
1% 22.71"0.19 23.3"0.04 0.10"0.02
3% 24.92"0.25 22.5"0.04 0.42"0.03
5% 18.60"0.11 20.3"0.05 3.33"0.14
a Values were estimated as described in the text.
even at concentrations of 5–20 mol%. Increasing the
amount of UDC to 20% led to a further decrease in
DH; in the cooling scans by about 55%, and in the
heating scans by about 50%. The change in T wasc
not significant and was in the range of y9 to y108C
for the heating scans and y12 to y138C for cooling
 .scans. Increased peak broadening DD was marked
 .at concentrations of 20% UDC Table 1 .
Addition of UDC to dimyristoylphosphatidyl-
choline reduced the enthalpy of the transition even at
concentrations of 0.1 mol%. The effect on peak
 .broadening DD could be observed at concentrations
of 3%. T was 22.58C, addition of 5% UDC led onlyc
to a minimal change in transition temperature to
 .20.38C Table 1, Fig. 1 .
3.2. Stability of ˝esicles
The vesicles used were LUV, data obtained by
laser light scattering have shown a homogeneous
suspension with a size of 100"10 nm polydisper-
.sity index 3 prior to centrifugation. After centrifuga-
tion the supernatant was investigated by laser light
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Fig. 1. Heating scans of the phase transition of dimyristoylphos-
 .  .phatidylcholine DMPC with increasing amounts of UDC. 1
 .  .100% DMPC; 2 99% DMPCq1% UDC; 3 97% DMPCq3%
 .UDC; 4 95% DMPCq5% UDC.
scattering, particles less -20 nm in size could be
detected. These particles were only induced by cen-
trifugal forces. The stabilizing effect of cholesterol in
LUV against centrifugal forces to the vesicles is seen
Fig. 2. Effect of UDC on phospholipid release induced by
..centrifugal forces: 100000= g from LUV containing different
 .  .amounts of cholesterol. 1 Control; 2 incubation with 0.1 mM
 .  .UDC; 3 incubation with 1 mM UDC; 4 incubation with 3 mM
UDC. Mean standard error of triplicate measurements: curve
 .  .  .  .1 s"3.7; curve 2 s"3.4; curve 3 s"4.1; curve 4 s
"4.0.
Fig. 3. Effect of UDC on cholesterol release induced by centrifu-
.gal forces: 100000= g from LUV containing different amounts
 .  .  .of cholesterol. 1 Control; 2 incubation with 0.1 mM UDC; 3
 .incubation with 1 mM UDC; 4 incubation with 3 mM UDC.
 .Mean standard error of triplicate measurements: curve 1 s"4.1;
 .  .  .curve 2 s"5.4; curve 3 s"2.1; curve 4 s"3.7.
 .in Fig. 2 curve 1 . Increasing the cholesterol content
of the membrane reduces the phospholipid release.
The greatest stabilizing effect was found with mem-
branes containing 40% cholesterol, which reduced the
phospholipid release from 44.3 to 11.5%. A further
increase in membrane cholesterol did not further
enhance the stability of the vesicles since the phos-
pholipid release then increased to 12.5%. The choles-
terol release induced by centrifugal forces was also
decreased by increasing the membrane cholesterol
 .Fig. 3, curve 1 . The most marked effect was found
with 40% membrane cholesterol cholesterol release
.10.6% ; in membranes with 10% cholesterol the re-
lease was 42.7%.
Similar results were found when the membrane
lipid release from LUV was measured after incuba-
tion with UDC. The greatest effect of UDC on mem-
brane stabilization was found when 100% EYL vesi-
cles were incubated with 3 mM UDC: a reduction in
the phospholipid release from 44.3 to 12.2% was
 .observed Fig. 2 .
Vesicle pelleting by bile salts could be excluded
since in control experiments with 3 mM CDC the
phospholipid release in the supernatant increased from
44.3 to 91.6%. In addition UDC was used in concen-
trations below the CMC excluding formation of lipid
aggregates.
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 .Fig. 4. Influence of UDC and CDC on the size of LUV. 1
 .Effect of CDC on LUV with 100% EYL and 2 containing 40%
 .of cholesterol. 3 Effect of UDC on LUV with 100% EYL and
 .4 containing 40% of cholesterol. Mean standard error of tripli-
 .  .cate measurements: curve 1 s"14; curve 2 s"12; curve
 .  .3 s"21; curve 4 s"19.
 .UDC also prevented cholesterol release Fig. 3 . In
vesicles containing 10% cholesterol, the cholesterol
release was reduced from 42.7% to 23.1% by incuba-
tion with 0.1 mM UDC. UDC concentrations up to 3
mM reduced cholesterol release to 12.8%. Vesicles
with a cholesterol content over 30% were not further
Fig. 5. CF release from LUV with EYL and different cholesterol
concentrations induced by CDC. Incubation time with bile salts:
60 sec. Mean standard error of triplicate measurements: curve for
100% EYL s"7.1.; curve for 10% Chols"5.3; curve for 20%
Chols"4.0; curve for 30% Chols"3.7; curve for 40% Chol
s"4.8; curve for 50% Chols"6.8.
 .stabilized by UDC Fig. 3 . Increasing the UDC
 .concentration Fig. 7 above the CMC increased the
phospholipid release to 33.8% in 100% EYL vesicles
 .control value 44.3% , indicating that UDC has no
effect on phospholipid and cholesterol release above
w xthe CMC of about 5.5 mM 15 .
3.3. Determination of ˝esicle size
The mean size of control vesicles measured by
laser light scattering was 100"10 nm polydisper-
.sity index 3 . An increase in vesicle size of 50–100%
was detected after incubation with CDC in a concen-
tration just below that required for vesicle solubiliza-
 .tion Fig. 4 , indicating that the bile saltrlipid ratio in
the membrane is increased. 100% EYL vesicles were
solubilized by concentrations of 1.1–1.25 mM CDC,
i.e., vesicle size was reduced below 20 nm. When the
cholesterol concentration of the vesicles was gradu-
ally increased, the CDC concentration required for
membrane solubilization also increased. In vesicles
containing 40% cholesterol, membrane solubilization
was found at CDC concentrations of 1.4–1.5 mM.
Cholesterol concentrations above 40% did not further
increase membrane stability.
In incubation experiments with UDC the size of
100% EYL vesicles remained constant up to concen-
Fig. 6. CF release from LUV with EYL and different cholesterol
concentrations induced by UDC. Incubation time with bile salts:
60 sec. Mean standard error of triplicate measurements: curve for
100% EYL s"6.5.; curve for 10% Chols"4.0; curve for 20%
Chols"4.5; curve for 30% Chols"3.1; curve for 40% Chol
s"5.9; curve for 50% Chols"7.7.
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trations of 5 mM UDC. Above this concentration
vesicle size increased dramatically and vesicle aggre-
gation possibly with the formation of multilamellar
.vesicles could be detected with a size greater than
 .1000 nm Fig. 4 , the polydispersity index was 5. By
increasing the cholesterol concentration vesicle ag-
gregation was shifted to higher UDC concentrations
 .7.5 mM UDC .
3.4. CF efflux
In preliminary experiments we investigated the
effect of bile salts on CF efflux for incubation times
up to 60 min. Equilibration of the system was reached
after 4–5 min, longer incubation times revealed no
more information on membrane permeability. The
most dramatic changes in membrane permeability
could be observed in the first minutes during bile
salts incubation. The percentage of CF in the super-
natant after 60, 120 and 240 s incubation with CDC
and UDC revealed a time-dependent increase of CF
efflux from EYL vesicles. In 100% EYL vesicles
CDC induced 10% CF efflux even at concentrations
below 0.05 mM. The CF efflux depended on the
 .cholesterol concentration of the vesicles Fig. 5 .
Increasing the cholesterol concentration decreased the
CF efflux. This effect was found up to cholesterol
concentrations of 40%. At cholesterol concentrations
above 40%, the CF efflux caused by bile salts in-
creased again.
 .Fig. 7. Influence of UDC on 100% EYL-LUV: 1 On vesicle
 .  .size, 2 on phospholipid release and 3 on CF release. Mean
 .standard error of triplicate measurements: curve 1 s"21; curve
 .  .2 s"3.9; curve 3 s"6.5.
 .  .Fig. 8. CF release from LUV with 100% EYL. 1 Control; 2
 .Incubation with 0.1 mM UDC; 3 Incubation with 0.25 mM
 .UDC and 0.1 mM CDC; 4 Incubation with 0.1 mM UDC and
 .0.1 mM CDC; 5 Incubation with 0.1 mM CDC. Mean standard
 .  .error of triplicate measurements: curve 1 s"5.9; curve 2 s
 .  .  ."6.2; curve 3 s"8.7; curve 4 s"7.5; curve 5 s"8.3.
Below 4 mM UDC induced only minor CF release
 .occurred from 100% EYL vesicles Fig. 6 . Incuba-
tion with 2 or 3 mM UDC induced a CF release of
9–18%. In concentrations below the CMC of UDC,
vesicle size remained constant and membrane lipids
 .were not released Fig. 7 . However, a distinct re-
 .lease of CF 80% and more was observed with
 .concentrations above 4 mM UDC Figs. 6 and 7 .
The release of CF from 100% EYL vesicles in-
duced by 0.1 mM CDC was )80% inhibited by
 .incubation with 0.1 mM UDC Fig. 8 . A similar
effect could be achieved by increasing the membrane
 .cholesterol Fig. 5 . The inhibitory effect of UDC
was not seen in vesicles containing cholesterol data
.not shown .
4. Discussion
By means of electron paramagnetic resonance
spectroscopy and with radioactively labelled bile salts,
it has been shown that UDC is incorporated into
w x w xhepatocyte plasma membranes 9 and LUV 16 . The
steroid nucleus of UDC is located in the apolar part
of the lipid bilayer decreasing membrane polarity and
preventing membrane damage caused by hydrophobic
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bile salts. Since in isolated cell membranes UDC
w xmolecules occupy a similar position to cholesterol 9 ,
the aim of the present study was to compare the
effects of UDC and cholesterol on membrane stabi-
lization using large unilamellar vesicles as a mem-
brane model.
Cholesterol is known to reduce the enthalpy of the
w xphase transition of phospholipid membranes 10,13 .
DSC revealed an effect of UDC on the phase transi-
tion that was comparable to that of cholesterol. Both
compounds progressively reduced the enthalpy of the
transition as their concentrations were increased. En-
thalpy was reduced by about 50% when the
UDC:phospholipid or cholesterol:phospholipid ratio
in the model membranes was as low as 1:5. In these
experiments glycerol was added as antifreeze, be-
cause of the low transition temperature of the lipid. In
experiments with dimyristoylphosphatidylcholine,
however, the effect of antifreeze on the phase transi-
tion was excluded and again an inhibitory effect
UDC on the enthalpy of the phase transition could be
observed, even at concentrations of 0.1%.
w xIn DSC studies with taurocholate 17 and tau-
w xrodeoxycholate 18 the transition temperature of
DPPC was changed, indicating that micellar struc-
tures affecting the cooperativity of the lipid. On the
contrary UDC did not change under our experimental
conditions the transition temperature of the lipid.
Cholesterol interacts with membranes and affects their
thermotropic properties by inserting into the hy-
drophobic part of the membrane. This leads to a
broadening, a reduction, or an elimination of the
phase transition without altering the phase transition
temperature as has been previously reported in the
w xliterature 13,19 . The thermal behaviour of a lipid is
an important factor in the permeability, fusion and
w xprotein binding of lipid membranes 11,20 . The simi-
lar effects of UDC and cholesterol on the phase
transition therefore indicate that these substances may
interact with lipids in a similar fashion. UDC inter-
acts with membrane lipids, ordering the chains and
w xdecreasing their motion as does cholesterol 21 . We
were unable to obtain data on order parameters using
EPR, since it was not possible to remove the bile
salts from the vesicle containing suspension without
destroying the membranes and previous studies have
shown that bile salts interact with lipid spin labels.
However, if bile salts are removed from the super-
natant, UDC decreases membrane polarity and fluid-
w xity 9 . Thus the DSC experiments complement our
EPR investigations.
Interactions between bile salts and phospholipid
membranes have also been described for C, DC and
w x w xCDC 22,23 . By means of NMR experiments 22 it
has been shown that C molecules are most probably
placed flat on the membrane surface rather than
intercalated between the phospholipid molecules.
However, deuterated DC and CDC, were found to be
incorporated perpendicularly into the surface of the
w xlecithin bilayer membrane 23 . The effect of bile
acids on membranes is induced by membrane binding
w x16 . The protonated form of the bile acids in the
w xmembranes depends on the pKa 16,24 , more polar
bile acids, e.g., taurine conjugated are expected not to
be protonated in the membrane. The pKa of UDC is
w xhigher than CDC 25 and in membranes is increased
w xby several pH units 24 . Under the experimental
conditions used in this study UDC is expected to be
protonated and membrane-bound. The steroid nucleus
of UDC is located in the center of the bilayer, the
polar carboxyl group oriented towards the aqueous
phase, while glyco- and tauroursodeoxycholate are
located in the interface, oriented with their polar side
w xchains on the membrane surface 9 . Since UDC is a
relatively hydrophilic bile salt as estimated with re-
versed phase high performance liquid chromatogra-
phy, incorporation could occur as a paired molecule,
thereby avoiding contact between its polar groups
w xand the fatty acid chains of the membrane 26 .
Cholesterol is incorporated into the membrane with
its hydroxyl group oriented to the aqueous surface
and the aliphatic chain aligned parallel to the acyl
w xchains in the center of the bilayer 11,20 . The steroid
nucleus is positioned along the first ten carbons of
the phospholipid chain. EPR studies suggest that the
steroid nucleus of UDC is located a few atoms deeper
than that of cholesterol, but in principle in the same
w xdomain 9 .
Although the steroid nucleus of UDC and choles-
terol are localized in the same domain of the plasma
membrane and decrease membrane fluidity, incuba-
tion of CF loaded vesicles with UDC below the CMC
induces slight CF release of about 4–18%. However,
by measuring the vesicle size, the polydispersity in-
dex and the phospholipid release from the mem-
branes, a disruption of the vesicles and the formation
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of mixed phospholipidrbile salt micelles was ex-
 .cluded Fig. 6 . It has been suggested that during
incubation of vesicles with bile salts, the number of
molecules in the outer leaflet of the bilayer increases,
and that the difference in the number of molecules in
the outer and inner leaflet results in a sudden mem-
brane foldover accompanied by a transient pore for-
w xmation 16 . After redistribution of UDC in both
leaflets of the bilayer, membranes were rapidly stabi-
lized and the CF release ceased. This could be an
explanation for the CF release in our experiments. In
the case of CDC, membrane foldover and pore forma-
tion may also be caused by interactions between the
hydroxygroups of the steroid nucleus.
CDC above the CMC solubilizes phospholipid
membranes to form mixed micelles with membrane
w xlipids 27 , whereas low concentrations of UDC stabi-
lize LUV membranes as does cholesterol. The stabi-
lizing effect of UDC was inversely correlated to the
cholesterol content of the membrane. No effect of
UDC was observed in vesicles with a membrane
cholesterol content of 30% and more. This phe-
nomenon may be due to the condensation of the
membrane by cholesterol molecules reducing the flu-
idity of the phophoslipid layers above the phase
w xtransition temperature 11,20 , thus preventing the
w xpenetration of bile salt molecules 16 .
w xPrevious investigators 28 have described a pro-
tective effect of tauroursodeoxycholate in concentra-
tions of up to 15 mM against the damaging effect of
taurodeoxycholate on vesicles containing 50%
w xcholesterol. Above the CMC 29,30 we obtained
 .similar data not shown for UDC. Above the CMC
UDC induced fusion of vesicles to multilamellar
 .aggregates Fig. 7 . Lipid aggregation was also shown
w xfor taurocholate above the CMC 31 . This phe-
nomenon may be induced by the formation of apolar
clusters on the membrane surface. Above a choles-
terolrlipid ratio of 1, cholesterol also induced vesicle
w xfusion 21 .
In low concentrations CDC increased the perme-
ability of the vesicles as shown by the CF release.
UDC also had a protective effect against CDC dam-
age, when vesicles were incubated in an equimolar
 .UDCrCDC-solution 0.1r0.1 mM . This effect could
be due to a molecular interaction of bile salts in the
w xbuffer milieu, as shown previously 9 , or UDC could
impede the penetration of CDC into the inner leaflet
of the bilayered membrane. The latter may be more
likely, since if the effect were merely a molecular
interaction in the incubation medium, the inhibition
of the CF release should be independent of the lipid
composition of the vesicles. However, since there
was no relevant inhibition of CF release by UDC in
cholesterol containing vesicles, a direct membrane
effect can be assumed. As shown above, this direct
membrane effect of UDC is inversely correlated to
the cholesterol concentration of the vesicles inhibit-
w xing the insertion of UDC 16 . Thus membrane-bound
UDC impedes the penetration of cholesterol into the
membrane.
The similarities between UDC and cholesterol con-
cerning their interaction with phospholipid mem-
branes may be of relevance for the therapeutic effect
of UDC. In cholestatic liver diseases liver plasma
membranes especially canalicular hepatocyte mem-
. w xbranes may change their lipid composition 32 ,
since during cholestasis the more hydrophobic ‘toxic’
bile salts seem to accumulate around the bile capillar-
w xies 33,34 . Since bile secretion in these patients is
reduced and retention of the more apolar, toxic bile
salts into blood occurs, similar alterations may occur
at basolateral hepatocyte membranes. One of the
therapeutic effects of UDC could be the maintenance
of membrane structure, stability and function.
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